85%Confidence
0Views
FDASource
2026-04-09Date
Summary
Teva faces a Class II recall for Octreotide Acetate due to sterility issues at its Greek contract manufacturer, indicating potential supply disruptions and reputational damage for this injectable drug. This highlights ongoing quality control risks in Teva's outsourced manufacturing network, which may lead to increased regulatory scrutiny and financial impacts.
Actionable: Monitor Teva's supply chain for further recalls and assess potential revenue impact from this product line.
AI Confidence: 85%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productOctreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmat
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now